Dalbavancin

Dalbavancin
Dalbavancin
Clinical data
Pregnancy cat.  ?
Legal status  ?
Routes Intravenous
Identifiers
CAS number 171500-79-1 YesY
ATC code J01XA04
PubChem CID 16134410
UNII 808UI9MS5K N
ChEMBL CHEMBL527063 N
Chemical data
Formula C88H100Cl2N10O28 
Mol. mass 1755.634 g/mol
 N(what is this?)  (verify)

Dalbavancin (INN, trade name Zeven) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely-used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).[1]

Dalbavancin (BI397) is a novel semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin.[2]

It possesses in vitro activity against a variety of Gram-positive pathogens[3][4] including MRSA and MRSE.[5] It is a once-weekly, two-dose antibiotic that Pfizer acquired when it bought Vicuron Pharmaceuticals in 2005.[6]

Clinical progress

Dalbavancin has undergone a phase III clinical trial for adults with complicated skin infections, but in Dec 2007 the FDA said more data was needed before approval.[6] On September 9, 2008, Pfizer announced that it will withdraw all marketing applications in order to conduct another Phase 3 clinical trial.[7] Durata Therapeutics acquired the rights to dalbavancin in December 2009 and has initiated two new Phase III clinical trials for treatment of acute bacterial skin and skin structure infections.[8]

References and notes

  1. ^ Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration
  2. ^ Scheinfeld NS. (May 2006). "Dalbavancin: A review for dermatologists.". Dermatology Online Journal 12 (4): 6..  PMID 17083861
  3. ^ Chen AY, Zervos MJ, Vazquez JA (2007). "Dalbavancin: a novel antimicrobial". Int. J. Clin. Pract. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMC 1890846. PMID 17362476. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1890846. 
  4. ^ Das B, Sarkar C, Biswas R, Pandey S (2008). "Review: dalbavancin-a novel lipoglycopeptide antimicrobial for gram positive pathogens". Pak J Pharm Sci 21 (1): 78–88. PMID 18166524. 
  5. ^ Dalbavancin: A Novel Lipoglycopeptide Antibacterial
  6. ^ a b UPDATE 1-Pfizer says US FDA wants more data on antibiotic. Dec 2007
  7. ^ "Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial" (Press release). Pfizer Inc.. 2008-09-09. http://www.businesswire.com/news/pfizer/20080909005943/en. Retrieved 2008-09-11. 
  8. ^ Durata Begins Dalbavancin Study Enrollment. Drug Discovery & Development - October 05, 2011.
v · d · eAntibacterials: cell envelope antibiotics (J01C-J01D)
Intracellular
inhibit peptidoglycan subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin) • DADAL/AR inhibitors (Cycloserine) • bactoprenol inhibitors (Bacitracin)
Glycopeptide
inhibit PG chain elongation: Vancomycin# (Oritavancin, Telavancin) • Teicoplanin (Dalbavancin) • Ramoplanin
β-lactams/
(inhibit PBP
cross-links)
Penicillins/
(penams)

Benzylpenicillin (G)#: Clometocillin • Benzathine benzylpenicillin#  • Procaine benzylpenicillin# • Azidocillin • Penamecillin

Phenoxymethylpenicillin (V)#: Propicillin • Benzathine phenoxymethylpenicillin • Pheneticillin
Penems
Biapenem • Ertapenem • antipseudomonal (Doripenem • Imipenem • Meropenem) • Panipenem
4th (antips-)
Ceftobiprole • Ceftaroline fosamil
Aztreonam • Tigemonam • Carumonam • Tabtoxin
Combinations
Other
polymyxins/detergent (Colistin, Polymyxin B) • depolarizing (Daptomycin) • hydrolyze NAM-NAG (Lysozyme) • Gramicidin

M: BAC

bact (clas)

gr+f/gr+a(t)/gr-p(c)/gr-o

drug(J1p, w, n, m, vacc)


Stub icon This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.